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Objectives: We compared the pharmacokinetics of moxifloxacin during rifampicin co-treatment or when dosed
alone in African patients with drug-susceptible recurrent TB.
Methods: Patients in the intervention arm of the Improving Retreatment Success (IMPRESS) randomized con-
trolled TB trial received 400 mg of moxifloxacin, with rifampicin, isoniazid and pyrazinamide in the treatment
regimen. Moxifloxacin concentrations were measured in plasma during rifampicin-based TB treatment and
again 4 weeks after treatment completion, when given alone as a single dose. Moxifloxacin concentration–time
data were analysed using non-linear mixed-effects models.
Results: We included 58 patients; 42 (72.4%) were HIV co-infected and 40 (95%) of these were on efavirenz-
based ART. Moxifloxacin pharmacokinetics was best described using a two-compartment disposition model with
first-order lagged absorption and elimination using a semi-mechanistic model describing hepatic extraction.
Oral clearance (CL/F) of moxifloxacin during rifampicin-based TB treatment was 24.3 L/h for a typical patient
(fat-free mass of 47 kg), resulting in an AUC of 16.5 mgh/L. This exposure was 7.8% lower than the AUC follow-
ing the single dose of moxifloxacin given alone after TB treatment completion. In HIV-co-infected patients taking
efavirenz-based ART, CL/F of moxifloxacin was increased by 42.4%, resulting in a further 30% reduction in moxi-
floxacin AUC.
Conclusions: Moxifloxacin clearance was high and plasma concentrations low in our patients overall.
Moxifloxacin AUC was further decreased by co-administration of efavirenz-based ART and, to a lesser extent, ri-
fampicin. The clinical relevance of the low moxifloxacin concentrations for TB treatment outcomes and the need
for moxifloxacin dose adjustment in the presence of rifampicin and efavirenz co-treatment need further
investigation.
Introduction
The WHO recommends moxifloxacin for the treatment of MDR TB1
and it is emerging as a key drug being investigated in shorter, novel
drug regimens for the treatment of drug-susceptible and MDR
TB.1–3 Moxifloxacin may be used for the treatment of drug-
susceptible TB, if intolerance develops to one of the drugs used in
standard first-line regimens or in patients with isoniazid monore-
sistance.4–6
The REMox7 and RIFAQUIN8 studies investigating moxifloxacin-
containing regimens for shortening the treatment of drug-
susceptible TB to 4 months failed to show non-inferiority for re-
lapse or treatment failure after 18 months of follow up, compared
with standard 6 month regimens.7,8Although there may be several
reasons for these results,9,10 given that AUC/MIC is the driver of
moxifloxacin efficacy, inadequate moxifloxacin concentrations in
plasma and at sites of action against Mycobacterium tuberculosis,
using standard 400 mg doses of moxifloxacin, have been
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suggested as a contributing factor.11 Furthermore, it is unclear
whether a known drug interaction with rifampicin results in clinic-
ally significant decreases in moxifloxacin plasma concentrations
that may have contributed to the outcomes of the REMox clinical
trial as no drug concentrations were measured in the REMox
study.7
Moxifloxacin is metabolized via glucuronide and sulphate con-
jugation by the cytosolic enzymes UDP-glucuronosyltransferase
(UGT) and sulphotransferase. Moxifloxacin is a substrate of the
drug transporter P-glycoprotein, involved in its absorption, distribu-
tion and elimination. Previous studies found that rifampicin co-
administration decreased moxifloxacin plasma concentrations by
up to 31%,12–15 due to rifampicin induction of glucuronosyltrans-
ferase, sulphotransferase and P-glycoprotein. However, rifampicin
may also have the paradoxical effect of net inhibition of
P-glycoprotein, which may result in higher absorption of co-
administered drugs.16 There are no data in African patients with TB
comparing moxifloxacin pharmacokinetics when dosed with or
without rifampicin. Variable pharmacokinetics of standard first-
line TB drugs have been described in African patients, in whom
high levels of host genetic variability in drug-metabolizing
and transporter enzymes and co-morbidities, including HIV, may
result in suboptimal TB drug concentrations and treatment out-
comes.17–19
In this study, we compared the pharmacokinetics of moxifloxa-
cin when co-administered with rifampicin or dosed alone in
African patients with drug-susceptible, recurrent TB, the majority
of whom were HIV co-infected and on efavirenz-based ART.
Patients and methods
Study design and setting
We conducted a sequential-design, prospective pharmacokinetic sub-study
within the ongoing Improving Retreatment Success (IMPRESS) open-label
randomized controlled trial (NCT02114684), from October 2013 in
KwaZulu-Natal, Durban, South Africa. The IMPRESS study was designed to
determine whether a moxifloxacin-containing regimen, substituting moxi-
floxacin for ethambutol, of 24 weeks duration is superior to a standard con-
trol regimen of 24 weeks duration in improving recurrent TB treatment
outcomes.
Participants
Patients in the intervention arm of the study, receiving moxifloxacin, who
provided informed consent to be included in the pharmacokinetic sub-
study had blood samples collected for pharmacokinetic analysis at pre-
defined timepoints during the study. All participants recruited to the study
were .18 years of age, had a past history of confirmed TB within the last
3 years, and had been diagnosed with sputum smear-positive, rifampicin-
susceptible M. tuberculosis based on microscopy and GeneXpert technol-
ogy. Both HIV-positive and -negative patients were included. Only patients
with no predefined laboratory or clinical abnormalities were included.
Drug regimens
Patients randomized to the intervention arm of the study received daily
400 mg of moxifloxacin (AveloxV
R
, Bayer Healthcare), weight-based rifampi-
cin at 450 or 600 mg, and 225 or 300 mg of isoniazid, for patients 38–54
and55 kg, respectively, during the 2 month intensive phase and 4 month
continuation phase of TB treatment. During the intensive phase of treat-
ment, pyrazinamide was used at 1500 and 2000 mg in patients between
38–54 and 55 kg, respectively. Patients who remained sputum smear or
culture positive continued on pyrazinamide beyond 2 months of treatment,
until sputum conversion. After the completion of TB treatment participants
were given a single dose of moxifloxacin following a washout period of
4 weeks. All patients received at least 50 mg of pyridoxine with study
drugs. There were no food restrictions in the pharmacokinetic study, al-
though the time of the last meal was recorded in relation to drug dose and
pharmacokinetic sample collection.
Follow-up
Patients were followed up for 24 months and clinical and safety monitoring
was done every 2 months for the first 6 months, or as clinically indicated.
Laboratory and safety investigations included haemoglobin as part of a
complete blood count, renal and hepatic biochemistry, total protein and
albumin determinations, and electrocardiogram monitoring. Sputum
smear microscopy and culture were done at predefined timepoints in the
study. HIV testing was done monthly in HIV-uninfected patients. HIV RNA
viral load [Roche AmpliPrep-COBAS Taqman 48 Analyzer platform (Roche
Molecular Diagnostics)] and CD4! T cell count (FACSCalibur flow cytometer,
Becton Dickinson Bioscience) were determined annually and viral load at
6 months. Adherence to TB treatment was measured using pill count,
based on the number of tablets dispensed, physically returned, reported re-
maining or lost, as well as participant self-report of missed or incomplete
doses in the 4 days prior to the day of study visit or pharmacokinetic sam-
pling. HIV-co-infected patients received standard first-line ART containing
efavirenz, emtricitabine and tenofovir. Treatment and prophylaxis for op-
portunistic infections and concomitant treatment used was recorded on
case report forms. Patients requiring iron- or zinc-containing supplements
or aluminium- and magnesium-containing antacids, known to affect the
pharmacokinetics of moxifloxacin20,21 were counselled to take these at
least 2–4 h before or after moxifloxacin dosing. Information relating to tim-
ing of dose for all drugs with known interaction potential with moxifloxacin
was recorded on case report forms.
Pharmacokinetic sample collection
Plasma samples were collected prior to drug dose and at 2.5, 6 and 24 h
after dose at months 1 and/or 2 during the intensive phase of TB treatment,
at month 6 during the continuation phase of TB treatment and 4 weeks
after the completion of TB treatment following a single dose of moxifloxacin.
Plasma, collected in EDTA tubes, was centrifuged at 3000 rpm, placed on ice
and immediately sent to the CAPRISA laboratory, to be stored in cryovials at
–80C within 1 h of collection. Moxifloxacin concentrations were quantified
in clinical plasma samples using validated HPLC–MS/MS at the KwaZulu-
Natal Research Institute for Tuberculosis and HIV (KRITH) pharmacology la-
boratory. The bioanalytical method was developed and validated according
to FDA guidelines (2011).22 Sample preparation included protein precipita-
tion with acetonitrile and subsequent dilution with water. Chromatographic
separation was achieved using a Zorbax C18, 3.5 lm, 50 mm%2.1 mm col-
umn and detection with an ABI Sciex 5500 QTrap mass spectrometer oper-
ated in positive mode. The following transitions were used; precursor
ion!product ion (all in units of m/z): moxifloxacin, 402.1!358.2 and
402.1!364.1. The internal standard used was ciprofloxacin: 331.6!231.0
and 331.6!288.1. Moxifloxacin was analysed isocratically with a 22%
acetonitrile/water/0.1% formic acid mobile phase. The injection volume was
2 lL and the total analytical run time was 5 min. The method was validated
over the concentration range of 50–5000 ng/mL. Overall precision, based on
quality control samples evaluated at low, medium and high concentrations,
during the validation and analysis of samples ranged from 8.4% to 19.4%
and accuracy ranged from 101.9% to 105%. Calculated carry-over at the
lower limit of quantification (LLOQ) was 5.4%. The LC–MS/MS system was
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Ethics approval for the study was provided by the Biomedical Research
Ethics Committee of the University of KwaZulu-Natal (BFC029/13) and the
Medicines Control Council of South Africa (MCC Ref:20130510).
Statistical analysis
The moxifloxacin concentration–time data were analysed using non-linear
mixed-effects (NLME) modelling, implemented with the software NONMEM
(version 7.3).23 Perl-speaks-NONMEM, Xpose and Pirana were used for
model diagnostics and to track model development.24 Additional plots and
post-modelling analysis were performed in R software25 via the RStudio
interface.26
A stepwise modelling approach was employed by starting with a struc-
tural model to describe drug absorption, distribution and elimination proc-
esses and then exploring the effect of covariates such as weight, age, sex,
rifampicin-based treatment, concurrent ART, adherence to TB treatment,
intake of iron and/or magnesium and renal and hepatic function. In particu-
lar, for moxifloxacin, the effects of rifampicin co-administration on CL, ab-
sorption and bioavailability were investigated.
The tested structural models included one- and two-compartment dis-
position kinetics with first-order elimination or a semi-mechanistic model
describing the effect of the liver both on systemic CL and first-pass extrac-
tion.27 For this latter approach, the moxifloxacin unbound fraction in
plasma was assumed to be 50%28 and a value of 50 L/h was used for hep-
atic plasma flow in a typical patient.29 To characterize the absorption pro-
cess, first-order lagged or transit compartment models were explored.30
Variability in pharmacokinetic parameters was included, assuming a log-
normal distribution to describe changes between patients [between-
subject variability (BSV)] and within the same patient but on different
dosing occasions [between-occasion variability (BOV)]. An adjustment par-
ameter was included in BOV in bioavailability to account for the variability in
reported dosing time of the dose administered prior to the pharmacokinetic
sampling day. Moxifloxacin concentration data below the nominal LLOQ of
the assay were included in the analysis; values ,10% of the LLOQ were
censored and included by imputing half of the censoring threshold, as sug-
gested by Beal.31 A combined additive and proportional error model was
used to describe the residual unexplained variability, with the additive com-
ponent bound to be at least 10% of the LLOQ.
Allometric scaling32 was used to account for the effect of body size on
the disposition parameters (the exponent was fixed to 0.75 for clearance
and 1 for volume parameters), including hepatic plasma flow in the semi-
mechanistic model. Fat-free mass (FFM), and fat mass were calculated
based on weight, height and sex as suggested by Janmahasatian et al.,33
and were explored as descriptors of body size along with total body weight,
as previously recommended.32 Covariate effects were evaluated and
included if they significantly improved the ability of the model to describe
the data. Model improvements were evaluated by inspecting diagnostic
plots, including visual predictive checks,34 and decreases in the objective
function value (DOFV), which is assumed to have a v2 distribution. Drops of
more than 3.84 points for the addition of one parameter were considered
significant at P,0.05. Finally, a non-parametric bootstrap with replacement
(n"300) was applied to assess the robustness of the parameter estimates
and obtain the 90% CIs.
Results
Baseline characteristics
Moxifloxacin concentration–time data were available from 58
patients, 209 pharmacokinetic profiles and a total of 822 sampling
timepoints. Median weight, FFM and age were 56.9 kg (IQR
51.1–65.2), 46.8 kg (IQR 42.5–50.3) and 37 years (IQR 31–42), re-
spectively. Forty-one (70.7%) patients were male and 42 (72.4%)
were HIV co-infected, with 40 (95%) on efavirenz-based ART
(Table 1). Of the 209 pharmacokinetic profiles and 822 timepoints
available, 204 pharmacokinetic profiles and 739 timepoints were
included in the analysis for 58 patients. Reasons for exclusion of
pharmacokinetic profiles and time-point data are available in
Supplementary data (available at JAC Online).
Moxifloxacin pharmacokinetics
Moxifloxacin pharmacokinetics were best described using a two-
compartment disposition model (when compared with one-
compartment DOFV 45, two additional parameters, P,0.001),
with first-order absorption and an absorption lag time, and elimin-
ation using the semi-mechanistic liver model describing first-pass
extraction (DOFV 24 compared with simple first-order elimination
from the central compartment, no additional parameters esti-
mated). Since very little information was available in the absorp-
tion phase, a prior was added to improve parameter estimation
and stabilize the model. Lognormal priors with 30% uncertainty
were used, with a typical value of 0.75 h for the absorption lag
time and 1.5 1/h for the absorption rate constant, as previously re-
ported by Zvada et al.35 in a similar population. A schematic dia-
gram of the final model is depicted in Figure 1 and a detailed
description of the semi-mechanistic liver model is provided in the
Supplementary data. The model parameter estimates are shown
in Table 2; these include parameters of the hepatic model, i.e.
Table 1. Baseline characteristics of patients in the IMPRESS intervention
arm pharmacokinetic study
Variable Result (N"58)
Age (years), median (IQR) 37 (31–42)
Male, n (%) 41 (70.7)
Race (black African/Caucasian/coloureda),
n (%)
56 (96.6)/1 (1.7)/1 (1.7)
Weight (kg), median (IQR) 56.9 (51.1–65.2)
Fat-free mass (kg) 46.8 (42.5–50.3)
BMI (kg/m2), median (IQR) 19.6 (18.0–23.3)
Alkaline phosphatase (IU/L), median (IQR) 74.0 (58.0–97.0)
Total protein (g/L), median (IQR) 77.0 (73.0–83.0)
Potassium (mmol/L), median (IQR) 4.5 (4.2–4.9)
Bilirubin total (mmol/L), median (IQR) 6.0 (5.0–9.0)
ALT (IU/L), median (IQR) 18.0 (16.0–30.0)
AST (IU/L), median (IQR) 27.0 (23.0–37.0)
Haemoglobin (g/dL), median (IQR) 11.8 (10.4–12.7)
Platelets (109/L), median (IQR) 407.0 (337.0–477.0)
Creatinine clearance (mL/min), median (IQR) 121.0 (97.0–136.0)
HIV status (positive/negative), n (%) 42 (72.4)/16 (27.6)
ART, n (%)b
Efavirenz! emtricitabine! tenofovir 40 (95.2)
Lopinavir/ritonavir! lamivudine! tenofovir 2 (4.8)
CD4! count (cells/mm3), median (IQR)b,c 277.0 (139.0–384.0)
Viral load (log10 copies/mL)
b,d 3.3 (1.3–4.2)
aMixed race.
bOnly for HIV-positive patients.
cFour missing data.
dFive missing data.
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intrinsic CL (which determines hepatic extraction) and pre-hepatic
bioavailability (fraction absorbed and reaching the liver). For ease
of interpretation, these values have been converted to oral clear-
ance (CL/F) using the formulas in the Supplementary data
(Appendix 2) and shown in Table 3.
The oral clearance of steady-state moxifloxacin when given as
part of TB treatment with rifampicin, isoniazid and pyrazinamide
was an estimated 24.3 L/h for a typical patient in the cohort (FFM
of 47 kg). When comparing the pharmacokinetic profiles observed
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Figure 1. Schematic diagram of the semi-mechanistic model describing the pharmacokinetics of moxifloxacin in patients with drug-susceptible re-
current TB. Tlag, absorption lag time; Fpre-H, pre-hepatic bioavailability; Ka, absorption rate constant; EH, hepatic extraction; CLint, (hepatic) clearance
intrinsic; fu, free (unbound) fraction of drug in plasma; QH, hepatic plasma flow; CLH, hepatic clearance; VC, volume of central compartment; VP, vol-
ume of peripheral compartment; Q, inter-compartmental clearance; QH, hepatic plasma flow.
Table 2. Population parameter estimates of moxifloxacin pharmacokinetics
Parameter description Typical value (95% CI)a Random variability (95% CI)a
Intrinsic CL during rifampicin-based TB treatment (L/h)b,c 48.5 (44.1, 54.1) BSV 14% (9.2, 19.4)
BOV 12.3% (0.1, 18.5)
Volume of central compartment (L)c 126 (109.6, 134.5) BSV 7% (0.1, 13.2)
Inter-compartmental CL (L/h)c 2.04 (1.58, 4.71) –
Volume of peripheral compartment (L)c 30.5 (22.2, 54.4) –
Pre-hepatic bioavailabilityd 1 fixed BOV 36.1% (26.9, 41.7)
Absorption lag time (h), priore 0.55 (0.45, 0.74) –
Absorption rate (Ka, 1/h), prior
e 2.95 (1.21, 3.42) BOV 104.5% (1.0, 121.0)
Hepatic plasma flow (L/h) 50 fixed
Moxifloxacin fraction unbound (%) 50% fixed
Change in intrinsic clearance while on single dose of moxifloxacin (%) #29% (#37, #22)
Change in pre-hepatic bioavailability while on single dose of moxifloxacin (%) #23% (#33, #13)
Change in intrinsic clearance while on efavirenz-based ART (%) !42.4% (33, 58)
Scaling factor for variability in bioavailability while on single dose of moxifloxacin (-fold)f 0.62 (0.39, 0.89)
Scaling factor for variability in bioavailability for unobserved doses (-fold)f 2.5 (1.75,3.92)
Proportional error (%) 17.5 (12.3, 21.7)
Additive error (mg/L) 0.011 (0.005, 0.017)
aObtained with a non-parametric bootstrap (n"300).
bIntrinsic CL of moxifloxacin when given at steady-state within rifampicin-based TB treatment and no efavirenz.
cAll CL and volume parameters have been allometrically scaled with FFM, and the typical values reported here refer to the typical patient, with FFM of
47 kg.
dPre-hepatic bioavailability is the fraction of the drug that is absorbed, crosses the gut wall unchanged, thus entering the portal vein and reaching the
liver.
eThese parameters were estimated using a prior, as detailed in text.
fThese scaling factors modulate the size of the between-occasion variability in pre-hepatic bioavailability for the sections of data indicated (single
dose and unobserved doses).
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moxifloxacin after completion of TB treatment, oral clearance was
found to decrease by 7.8%, resulting in higher exposure.
Interestingly, the model identified a dual effect: a 29% decrease in
intrinsic CL (DOFV 29, one additional parameter, P,0.001) and a
concomitant 23% decrease in pre-hepatic bioavailability (DOFV 23,
one additional parameter, P,0.001). Additionally, a 42.4% in-
crease in oral clearance was observed both during and after TB
treatment in HIV-co-infected patients treated with efavirenz-
based ART (DOFV 46, one additional parameter, P,0.001). The
model described the effect of efavirenz as an increase in intrinsic
clearance, i.e. hepatic enzymatic activity.
The effect of body size on clearance and volume parameters
was captured with allometric scaling and best described using FFM
as a body size descriptor (DOFV 14, as opposed to total body
weight). After including the effect of body size, efavirenz and
rifampicin-based TB treatment, there was small random BSV
(14%) and BOV (12%) in moxifloxacin clearance. However, 36%
BOV was found for pre-hepatic bioavailability (i.e. before the effect
of hepatic extraction).This variability was smaller for the exposures
observed in the single-dose visit, after the end of TB treatment.
This was described in the model with a scaling factor estimated to
be 0.62 for the BOV in pre-hepatic bioavailability (DOFV 9, one add-
itional parameter, P"0.003).
On the other hand, the pre-dose concentrations on the day
of the pharmacokinetic visit were characterized by a larger vari-
ability than the profile obtained after the observed dose in the
clinic. This was included in the model by including a scaling fac-
tor estimated to be 2.5 for the BOV in pre-hepatic bioavailability
for all data obtained after an unobserved dose, taken by a pa-
tient prior to the observed dose in the clinic on the day of phar-
macokinetic sampling (DOFV 48, one additional parameter,
P,0.001). This larger variability was tested and included in the
model to reflect the larger uncertainty affecting self-reported
dosing information.
The visual predictive check in Figure 2 provides an overview of
the concentrations observed in the study and shows that the
model described the data adequately.
A summary of values of CL and model-predicted AUC for a typ-
ical patient in the different dosing scenarios (steady-state within
TB treatment, or single dose alone, with or without concomitant
efavirenz) is provided in Table 3. A visual depiction of the individual
AUC and Cmax observed in our cohort is presented in Figure 3.
Discussion
In our cohort of drug-susceptible TB patients, we found low moxi-
floxacin concentrations (AUC) during concomitant rifampicin-
based TB treatment. Higher concentrations (8%), but still low
overall, were observed 1 month after discontinuation of rifampicin,
when a single dose of moxifloxacin was administered for compari-
son. Notably, the increased exposure observed when a single dose
of moxifloxacin was given alone after the end of TB treatment was
found to be the result of two opposing effects: 30% decreased in-
trinsic clearance and decreased bioavailability. Moreover, in HIV-
co-infected patients on efavirenz-based ART, clearance was
increased by 42% when compared with HIV-uninfected patients
or those on lopinavir/ritonavir-based ART. The effect of efavirenz,
which lowered the AUC by 30%, was present both when moxi-
floxacin was given alone and when it was given within rifampicin-
based TB treatment.
Our findings are in keeping with previous studies12–15,36 investi-
gating the effect of rifampicin co-administration on moxifloxacin
drug concentrations in healthy individuals and TB patients, show-
ing lower concentrations of moxifloxacin due to rifampicin co-
administration. However, these studies reported variable effects of
rifampicin co-treatment on moxifloxacin exposure. Bioavailability
studies,12–14 using cross-over or sequential study designs to limit
inter-patient variability, and intensive pharmacokinetic sampling
demonstrated much higher differences in steady-state moxifloxa-
cin AUC (27%–31%) without concomitant rifampicin compared
with studies in real-world settings,15,36 which may be limited by
the heterogeneity between the groups compared and the small
sample sizes reported. In our study, the model estimated an
30% decrease in intrinsic CL when moxifloxacin was given alone
as opposed to during rifampicin-based TB treatment. On the other
hand, the model also estimated a decrease in bioavailability for
single-dose moxifloxacin pharmacokinetics when given alone
after TB treatment completion. These two phenomena had oppos-
ite effects on moxifloxacin concentrations and the reasons are not
entirely clear. Several explanations are plausible. Firstly, moxifloxa-
cin AUC at steady-state has been shown to be moderately higher
(30% for 400 mg once daily) than after the first or a single dose
of moxifloxacin37 as used in our study, suggesting that the differ-
ence shown in pre-hepatic bioavailability may be a consequence
of single-dose versus steady-state dosing. Secondly, it is possible
that rifampicin, given concomitantly, increases the absorption of

















CL/F (%) AUC (mgh/L)a
Steady-state yes no 48.5 33 100 (reference) 24.3 reference 16.5
Steady-state yes yes 69.1 41 100 34.5 !42.4 11.6
Single doseb no no 34.4 26 77 22.4 #7.8 17.9
Single doseb no yes 49.0 33 77 31.8 !31.3 12.6
RIF, rifampicin; EFV, efavirenz.
The typical values reported here refer to an individual with FFM of 47 kg (the median in our cohort).
aAUC for a dose of 400 mg.
bAfter completion of TB treatment.
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moxifloxacin; this may be due to net inhibition of P-glycoprotein by
rifampicin during the absorption phase, as has been previously re-
ported with digoxin.16 This suggests that the true effect of rifampi-
cin co-treatment may be larger and closer to the 30% lower AUC
demonstrated by previous studies,12–14 compared with moxifloxa-
cin alone.
The higher clearance and lower moxifloxacin concentrations in
HIV-co-infected patients on efavirenz-based ART has not been pre-
viously described. Efavirenz induces the activity of UGT,38,39
involved in moxifloxacin metabolism. There is evidence of efavir-
enz decreasing concentrations of other antiretroviral drugs metab-
olized by UGT, such as dolutegravir, by up to 57%.39 There have
been conflicting reports of the effect of HIV co-infection on TB
drugs, with some studies reporting decreased drug concentra-
tions40,41 while others found non-significant or no changes.42 It is
unclear whether the effect on clearance and AUC seen in those
HIV-co-infected patients who are on efavirenz are due to the in-
duction of UGT, HIV co-infection or a combination of these. There
were two HIV-co-infected patients who were on lopinavir/
ritonavir-based ART, and no decrease in moxifloxacin clearance
could be observed in any of the seven pharmacokinetic profiles
contributed by these patients, but the small numbers limit our abil-
ity to draw reliable conclusions about this observation. These find-
ings are nevertheless concerning, given that this interaction may
also impact moxifloxacin exposure in HIV-co-infected patients on
efavirenz-based ART taking moxifloxacin-containing MDR TB treat-
ment or in studies using moxifloxacin in novel drug regimens,3 and
need confirmation in other studies.
The plasma concentrations of moxifloxacin achieved in our pa-
tients are low regardless of efavirenz or rifampicin co-treatment,
when compared with previous reports.36,43–47 Moxifloxacin ex-
hibits extensive inter-individual variability in pharmacokinetic par-
ameters in healthy volunteers and patients with TB, with wide
ranges in AUC, Cmax and CL/F values. AUC values between 8.5 and
140 mgh/L and CL/F between 10 and 30.6 L/h have been reported
in previous studies using 400 mg moxifloxacin doses.43,44,48,49
African populations have shown high levels of host genetic diver-
sity and increased variation in drug metabolizing and transport
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Figure 2. Visual predictive check (VPC) stratified by co-administration with rifampicin and/or efavirenz. The dashed and solid lines are the 5th percentile,
median and 95th percentile of the observed concentrations, while the shaded regions represent the corresponding 95% CIs for the same percentiles.
The sub-plot in each stratum shows the same VPC with a logarithmic transformation applied to the y-axis. SS, steady-state; SD, single dose; MXF, moxi-
floxacin; RIF, rifampicin; EFV, efavirenz. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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enzymes, shown to result in lower drug concentrations and vari-
ation in drug response to other first-line TB drugs.17,18,50
We acknowledge several limitations. Firstly, we used relatively
sparse pharmacokinetic sampling methods at each pharmacokinetic
visit, a choice that may limit the precision of the individual estimates
of exposure. However, we employed NLME modelling for the inter-
pretation of the data; this analysis technique is designed to handle
sparse data well, since it pools information across the entire popula-
tion and is able to robustly identify population parameters, including
typical values, variability and covariate effects.51 Furthermore, phar-
macokinetic sampling around 2 and 6 h after dose has been shown
to provide reasonably accurate estimates of moxifloxacin AUC in pre-
vious studies.52 A second limitation may be due to the fact that
moxifloxacin pharmacokinetic parameters (CL/F and AUC) during TB
treatment compared with dosing after completion of TB treatment
may differ as a result of changes in patient physiology, increased
weight and improved disease status. In our model, we have included
the effect of body size to account for the effects of rifampicin and
efavirenz on moxifloxacin pharmacokinetics. However, several other
potential confounding factors, including genetic variability, may limit
our model’s ability to robustly quantify the contribution of each sep-
arate factor. Thirdly, the study was not designed to determine the
impact of the efavirenz interaction on moxifloxacin, hence efavirenz
drug concentrations, known to have high variability in exposure,53
were not determined. Fourthly, our study used a single dose of moxi-
floxacin given after completion of TB treatment and compared with
moxifloxacin at steady-state given concomitantly with rifampicin. It
is possible that changes in the pharmacokinetics of moxifloxacin be-
tween single-dose and steady-state treatment may be responsible
for the observed increase in pre-hepatic bioavailability. In this case,
the actual effect of rifampicin co-administration would only be the
30% increase in intrinsic CL, resulting in decreases in moxifloxacin
AUC similar to those reported in previous studies.12–14 Finally, phar-
macokinetic sampling was not ideal, as hospitalization of
ambulatory patients overnight, to minimize dosing errors and stand-
ardize sampling conditions, was not feasible within our study.
In conclusion, we found high CL and resulting low moxifloxacin
concentrations (AUC) in South African patients with drug-
susceptible, recurrent TB, further decreased by co-treatment with
rifampicin and efavirenz-based ART. The clinical relevance of the
low moxifloxacin concentrations is unclear, but the detected inter-
actions, especially the efavirenz effect on moxifloxacin, warrants
further investigation in studies to assess the need for dose adjust-
ments and impact on TB treatment outcomes.
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